Efficacy of adding Glucose Co-transporter 2 -Inhibitors in Treatment of Non-Valvular Paroxysmal Atrial Fibrillation

Document Type : Original Article

Authors

Department of Cardiology, Faculty of Medicine, Aswan University

Abstract

Background: In individuals with type 2 diabetes mellitus, SGLT2 inhibitors have been demonstrated to lower blood pressure, decrease weight, improve left ventricular remodeling, and decrease hospitalization for heart failure and cardiovascular death. Objectives: The aim of this study was to evaluate the efficacy of SGLT2 inhibitors on the AF cardiovascular outcome. Methodology: This single-blinded randomized controlled trial was carried out on 60 cases with non-valvular paroxysmal atrial fibrillation at the cardiology department, Aswan University Hospitals. Results: the change in LAD% and LAV-i% was significantly lower in group A (those who received SGLT2 inhibitors) compared to group B (those who did not receive SGLT2 inhibitors), both in absolute terms and relative terms. In the same way, LAS absolute and relative % change showed a significant improvement in the study group compared to control. After adjusting for all correlates, it was found that adding SGLT-2 to the standard treatment resulted in reduction of the risk of MACE by 32% (AOR= 0.678, 95% CI; 0.071 – 0.984, p=0.043) compared with those treated with the standard regimen. Conclusion: the addition of SGLT-2I to patients’ existing guideline-directed medical therapy for non-valvular paroxysmal AF was found to be independently associated with reduction in the short-term adverse effects of the disease.

Keywords

Main Subjects

Aswan University Medical Journal
Volume 5, Issue 3
September 2025
Pages 126-134

Files

Share

How to cite

Statistics